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Enbing Tian1, Haiping Tang2, Renhua Xu1, Chongdong Liu1, Haiteng Deng2* and Qingtao Wang1*Abstract
Azacytidine is an inhibitor of DNA methyltransferase and is known to be an anti-leukemic agent to induce cancer
cell apoptosis. In the present study, multiple myeloma cells were treated with azacytidine at clinically relevant
concentrations to induce necrosis through oxidative stress. Necrotic myeloma cells exhibit unique characteristics,
including enrichment of the cell-bound albumin and overexpression of endoplasmic reticulum (ER)- and
mitochondrial-specific chaperones, which were not observed in other necrotic cells, including HUH-7, A2780, A549,
and Hoc1a. Proteomic analysis shows that HSP60 is the most abundant up-regulated mitochondrial specific
chaperone, and azacytidine-induced overexpression of HSP60 is confirmed by western blot analysis. In contrast,
expression levels of cytosolic chaperones such as HSP90 and HSP71 were down-regulated in azacytidine-treated
myeloma cells, concomitant with an increase of these chaperones in the cell culture medium, suggesting that
mitochondrial chaperones and cytosolic chaperones behave differently in necrotic myeloma cells; ER- and
mitochondrial-chaperones being retained, and cytosolic chaperones being released into the cell culture medium
through the ruptured cell membrane. Our data suggest that HSP60 is potentially a new target for multiple
myeloma chemotherapy.
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Multiple myeloma (MM) is a clonal B-cell disorder in
which malignant plasma cells (PC) accumulate in the
bone marrow, resulting in lytic bone lesions and exces-
sive amounts of monoclonal proteins. It accounts for
10% of hematologic malignancies. Although therapeutic
interventions have been developed and the overall sur-
vival has been improved over the last decade [1], mye-
loma is still incurable and most multiple myeloma
patients who survive initial treatment will develop drug
resistance, and eventually relapse. Development of new
therapeutic interventions is strikingly needed for in-
creasing patient survival rate. It has been shown that
abnormal methylation of tumor suppressor genes is a
common event in malignant plasma cell disorders [2-4]
and aberrant global methylation patterns also affect the
molecular pathogenesis of myeloma [3]. Azacytidine, a
ring analog of the naturally occurring pyrimidine nucleo-
side cytidine, is an inhibitor of DNA methyltransferase.* Correspondence: dht@tsinghua.edu.cn; wqt36@163.com
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reproduction in any medium, provided the orFollowing incorporation into DNA, azacytidine is cap-
able of covalently binding to DNA methyltransferase,
resulting in hypomethylation and transcriptional reacti-
vation of some silenced genes. This has led to develop-
ment of azacytidine as a therapeutic anti-cancer agent.
Azacytidine has been used to treat patients with myelo-
dysplastic syndrome and acute myeloid leukemia at the
dose of 75-100 mg/day [5-7]. In vitro studies have shown
that azacytidine alone or in combination with other
antitumor agents induces tumor cell apoptosis. It has
been reported that azacytidine induced ATR-mediated
DNA double-strand break responses, apoptosis, and
synergistic cytotoxicity in multiple myeloma cells [8]. It
has also been demonstrated that a combination of azacy-
tidine and arsenic trioxide generates a synergistic anti-
tumor activity in myeloma [9]. Moreover, azacytidine
has been shown to activate the interleukin-6 and nuclear
factor-kB signaling pathways [10], and to induce overex-
pression of semenogelin I in myeloma cells [11]. To the
best of our knowledge, azacytidine induced necrosis in
myeloma cells has not yet been reported.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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istics of apoptosis and autophagy [12-16]. Over the last
several years, the occurrence and course of necrosis was
found to be programmed and tightly regulated. Extensive
studies show that death ligands (e.g., CD95L, TNF and
TNF-related apoptosis-inducing ligand) induce caspase-
independent necrotic-like cell death that relies on the
activity of the death domain (DD)-containing kinase
RIP1. Although the induction mechanisms of necrosis
are becoming increasingly clear, the execution of this
process remains somewhat elusive. Necrosis is accom-
panied by a complex sequence of cellular processes
including mitochondrial dysfunction with enhanced gen-
eration of reactive oxygen species (ROS) and ATP deple-
tion, proteolysis by calpains and cathepsins, and early
plasma membrane rupture. One important consequence
of necrosis is the induction of immunogenic responses
pursuant to the release of immunogens from necrotic
cells [17-20]. Basu and colleagues reported that heat
shock proteins (HSPs) including gp96, calreticulin,
HSP90 and HSP72 were released into the culture super-
natant from necrotic cells in response to freeze thaw,
but not from apoptotic cells [21,22]. It was further
shown that the released HSPs activated the NF-κB path-
way, stimulated macrophages to secrete cytokines, in-
duced the expression of co-stimulatory molecules, and
enhanced antigen presentation in dendritic cells [23-28].
A few studies have been reported on necrosis of mye-
loma cells. Kigamicin, a compound derived from actino-
mycetes, induces necrosis in human myeloma cells by
inhibition of cyclin D1, p21, p-AKT, and p-ERK [29]. A
D-amino acid-containing peptide HYD1 increases the
reactive oxygen species production, leading to necrotic
cell death in multiple myeloma cells [30]. When cells are
treated with azacytidine, not only DNA methyltrans-
ferase are inhibited, but ROS generation is also observed
[31]. For example, ROS generation is used as an indica-
tor for the synergistic and cytotoxic effects of azacytidine
in AML and acute lymphoblastic leukemia cells [32,33].
Within cells, mitochondria are susceptible targets for
oxidant stress. ROS can modify mitochondrial lipids,
proteins, and DNA. The lack of histones in mtDNA also
makes mitochondria more vulnerable to oxidative stress
[34,35]. Oxidative stress also may lead to modifications
and alterations of endoplasmic reticulum (ER) chaperone
proteins [36], causing the accumulation of unfolded or
misfolded proteins, and decreases in protein synthesis.
In the present work, we show that azacytidine-treatment
induces necrosis of myeloma cells through oxidative
stress, and that necrotic myeloma cells exhibit unique
characteristics, including enrichment of cell-bound al-
bumin and overexpression of the ER- and mitochon-
drial-specific chaperones. Expression of HSP60 has been




RPMI1640 medium, phosphate-buffered saline (PBS)
and fetal bovine serum were purchased from Wisent
(Montreal, QC) and used without further purification.
Dithiothreitol (DTT) was purchased from Merck
(Whitehouse Station, NJ). Sequencing grade modified
trypsin was purchased from Promega (Fitchburg, WI).
5-azacytidine, iodoacetamide (IAA) and RNase A were
purchased from Sigma (St Louis, MO). Dimethyl sulfoxide
was purchased from Applichem (St Louis, MO). A BCA
protein assay kit was purchased from Solarbio (Tongzhou
District, Beijing). TMT® Mass Tagging Kits and Reagents
were purchased from Thermo Scientific (Rockford, IL).
Cell Culture and Sample Preparation
Human MM cell line U266 was purchased from the
Tumor Cell Bank of Chinese Academy of Medical
Sciences (Beijing, China), and NCI-H929 and RPMI-
8226 cells were kindly provided by Dr. Wenming Chen
(Beijing Chao-Yang Hospital Affiliated to the Capital
University of Medical Science). All three cell lines were
cultured in RPMI 1640 (Wisent) containing 10% or 15%
fetal bovine serum with 100 units/mL penicillin and
100 μg/mL streptomycin at 37°C in a humidified incuba-
tor with 5% CO2. Prior to treatment, cells were cultured
for at least 12 h to reach exponential growth phase. Cells
were treated with azacytidine dissolved in dimethyl sulf-
oxide and the control cells were treated with the same
amount of DMSO for the same time periods. After treat-
ments, cells were washed twice with ice-cold PBS and
lysed with RIPA lysis buffer (25 mmol/L Tris-HCl
pH 7.6, 150 mmol/L NaCl, 0.1% SDS, 1% NP-40, 1%
sodium deoxycholate, 1 mmol/L PMSF, and Roche
Complete Protease Inhibitor Cocktail) for 30 min on ice.
Cell lysates were clarified by centrifugation at 14, 000 ×g
for 20 min at 4°C. The protein concentration in the
supernatant of each sample was determined using a
BCA protein assay kit.
Protein Separation by 1D SDS-PAGE and Proteomics
Analysis
Equal amount of proteins from untreated- and azacyti-
dine-treated samples (about 30 μg) were separated by
1D SDS-PAGE, respectively. The gel bands of interest
were excised from the gel, reduced with 25 mM of DTT
and alkylated with 55 mM iodoacetamide. In gel diges-
tion was then carried out with sequencing grade modi-
fied trypsin in 50 mM ammonium bicarbonate at 37°C
overnight. Peptides were extracted twice with 0.1%
trifluoroacetic acid in 50% acetonitrile aqueous solution
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speedvac to reduce the volume. To analyze the proteins
in the cell culture medium of untreated and azacytidine-
treated U266 cells, cells were cultured in RPMI 1640
medium containing 0.5% fetal bovine serum for 48 h
and the culture mediums were collected. Proteins from
the same volume of cell culture mediums were separated
by 1D SDS-PAGE, and the gel bands were excised and
digested with trypsin. For protein quantitation, peptides
from different samples were labeled with TMT
reagents purchased from Thermo-Pierce Biotechnology
(Rockford, IL) according to the manufacturer’s instruc-
tions. Briefly, TMT reagents were dissolved in anhydrous
acetonitrile. Labeling reaction was carried out by incuba-
tion of tryptic peptides with the TMT reagents for 1 h at
room temperature, and the reaction was quenched with
hydroxylamine. TMT-labeled peptides were desalted
using the stage tips.
For LC-MS/MS analysis, the digestion product was
separated by a 65 min gradient elution at a flow rate
0.250 μL/min with an EASY-nLCII™ integrated nano-
HPLC system (Proxeon, Denmark) which was directly
interfaced with a Thermo LTQ-Orbitrap mass spectrom-
eter. The analytical column was a home-made fused sil-
ica capillary column (75 μm ID, 150 mm length;
Upchurch, Oak Harbor, WA) packed with C-18 resin
(300 Å, 5 μm, Varian, Lexington, MA). Mobile phase A
consisted of 0.1% formic acid, and mobile phase B
consisted of 100% acetonitrile and 0.1% formic acid. The
LTQ-Orbitrap mass spectrometer was operated in the
data-dependent acquisition mode using Xcalibur 2.0.7
software and there was a single full-scan mass spectrum
in the Orbitrap (m/z 400 to m/z 1800, 30,000 resolution)
followed by 20 data-dependent MS/MS scans in the ion
trap at 35% normalized collision energy (CID). The MS/
MS spectra from each LC-MS/MS run were searched
against the selected database using an in-house Prote-
ome Discovery searching algorithm. For quantitation by
TMT labeling, TMT-labeled peptides were analyzed by
nano-LC-MS/MS with a Q Exactive mass spectrometer
that was also operated in the data-dependent acquisition
mode using the Xcalibur 2.1.2 software and there was a
single full-scan mass spectrum in an Orbitrap (m/z 350
to m/z 1600 Da) followed by 10 MS/MS scans. The MS/
MS spectra from each LC-MS/MS run were analyzed
using Proteome Discoverer (Version 1.3) for protein
identification and quantitation. Intensity ratios of the
TMT reporter ions were used to determine relative con-
centrations of labeled proteins.
The search criteria were as follows: full tryptic specifi-
city was required; one missed cleavages was allowed;
carbamidomethylation was set as fixed modification; oxi-
dation (M) was set as variable modification; precursor
ion mass tolerances were set at 10 ppm for all MSacquired in the Orbitrap mass analyzer; and the frag-
ment ion mass tolerance was set at 0.8 Da for all MS/
MS spectra acquired in the linear ion trap. A proteins
was designated as a “hit” only when 2 or more unique
peptides with high confidence scores (FDR < 1%) were
identified and their corresponding MS/MS spectra were
manually inspected. When several proteins matched the
same sets of peptides, only the proteins with the greater
percentage of coverage was selected. Significance was
regarded only when the ratio of spectral counts between
two groups were more than 2 or less than 0.5.
DNA Fragment Assay
DNA fragment assay was performed following the pro-
cedure described by Mazars et al [37]. Briefly, cells were
washed with PBS twice and collected by centrifugation.
Cells were suspended in 250 μl lysis buffer (1% NP-40,
20 mM EDTA, 50 mM Tris-HCl, pH 7.5). The superna-
tants were collected by centrifugation for 5 min at
1,600 × g. The supernatant was incubated with 0.71 mg/
ml RNase A for 2 h at 56°C. Then 100 μg/ml pronase E
was added and incubated with the supernatants over-
night at 37°C. DNA fragments were precipitated with 0.5
volumes of 10 M ammonium acetate and 2 volumes of
ethanol at -20°C for 12 h and centrifugated for 15 min at
15,000 ×g. The precipitate was washed with 70% ethanol
and resuspended in loading buffer. Electrophoresis was
performed in 0.5 × Tris-borate-EDTA buffer for 30 min.
Flow Cytometry
Cells were spun down at 1000 ×g for 5 min. The
medium was discarded and washed with PBS twice. Cells
were resuspended in 75% ethanol, vortexed to mix
briefly, and fixed at 4°C overnight. After vortex, the fixed
cells were re-suspended with PBS solution containing
Propidium Iodide (PI) (50 μg/ml), followed by RNaseA
treatment (1 mg/ml) for 30 min at 37°C and analyzed
with a BD FACSCalibur™ Flow Cytometer using 488 nm
excitation and a 515 nm bandpass filter for fluorescein
detection and a filter >560 nm for PI detection. Dot
plots and histograms were analyzed by CellQuest Pro
software (BD Biosciences, Heidelberg, Germany).
Western Blot Analysis
Untreated- and azacytidine treated-cells were collected
and lysed on ice with Biyuntian cell lysis buffer
containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1%
Triton X-100, and sodium pyrophosphate, ß-glycero-
phosphate, EDTA, and Na3VO4 for Western and IP
supplied with the protease inhibitor cocktail. The super-
natants were collected after centrifugation at 14,000 ×g
for 10 min at 4°C. Protein concentrations were deter-
mined using the BCA protein assay kit. Proteins were
separated on a 12% SDS-PAGE gel and transferred onto
Figure 1 Percentage of necrosis-related cell death in U266 cells
treated with azacytidine (0–80 μM) for 24 h. Results are
expressed as the mean of three experiments. Significant necrosis
was observed with 5 μM azacytidine treatment.
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blocking with 5% nonfat milk for 2 h at room temperature,
the membrane was incubated overnight at 4°C with 1000×
diluted primary antibody, washed with PBST buffer for 3
times, then incubated with 1000× diluted anti-mouse or
anti-rabbit secondary antibody labeled with HRP at room
temperature for 2 h. The membrane was further washed
with PBST buffer 3 times and developed using the Enlight
Kit (Engreen, China). Glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) was detected with anti- GAPDH
antibody as an internal control.
Quantitative real-time PCR (qPCR)
Cells were harvested after being treated with azacytidine
for different periods of time. Total RNA was extracted
by the SV Total RNA Isolation System. cDNA was syn-
thesized from 4 μg total RNA using the GoScriptTM Re-
verse Transcription System. All qPCR was performed
using the Roche LightCycler® 480II Detection System
with SYBR green incorporation according to the manu-
facturer’s instructions. The primers were either designed
by using the Primer Premier 5 software or from Primer
Bank (http://pga.mgh.harvard.edu/primerbank/). To pre-
vent amplification of genomic DNA, all target primers
span exon-exon junctions. The specific PCR products
were confirmed by melting curve analysis. Relative expres-
sion was analyzed using the 2-ΔΔCt method. Primer se-
quences for qPCR are listed in Additional file 1: Table S1.
Co-immunoprecipitation
Cells were lysed with Biyuntian cell lysis buffer for
Western and IP supplied with the protease inhibitor
cocktail. The protein concentrations of the cell lysates
were determined using a BCA assay. The protein A/G
agarose beads were washed three times with cell lysis buf-
fer. 2 mg of the cell lysate was incubated with 6 μg anti-
bovine albumin antibody and 20 μl protein A/G agarose
beads overnight at 4°C. The beads were centrifuged at
1000 ×g for 1 min and washed three times with the cell
lysis buffer, and proteins bound to the Protein A/G agar-
ose beads were then eluted by boiling the beads for 5 min
in 1 × SDS loading buffer. Each eluent was separated by
1D SDS-PAGE followed by western blot analysis.
Detection of Reactive Oxygen Species (ROS) in Untreated
and Azacytidine-treated Cells
ROS in untreated and azacytidine-treated cells was
detected using an Image-iT™ LIVE Green Reactive
Oxygen Species Detection Kit (Molecular Probes, Inc.
Eugene, OR) following the manufacturer’s instructions.
Briefly, the cells were collected by centrifugation and
washed once with warm HBSS/Ca/Mg. Cells were re-
suspended with 500 μl of the 25 μM carboxy-H2DCFDA
working solution for 25 min at 37°C, followed byaddition of the Hoechst 33342 reagent to the reaction
mixture at a final concentration of 1.0 μM and incuba-
tion for 5 min. The final products were washed gently
with 1 ml HBSS/Ca/Mg immediately followed by im-
aging with Zeiss 710 Confocal Microscopy.
Results and discussion
Azacytidine induces myeloma cell necrosis through
oxidative stress
Three myeloma cell lines U266, NCI-H929, and
RPMI8226 were treated with azacytidine at different
concentrations. All three cell lines showed the identical
morphological changes upon azacytidine treatment.
FACS analysis showed that the percentage of necrotic
cells was 22% when cells were treated with 5 μM
azacytidine for 24 h, increasing to 38% when treated
with 80 μM azacytidine for 24 h (Figure 1). Morpho-
logical features of the dying cells were consistent with
the cell necrosis. Images of cell morphology in un-
treated, hydrogen peroxide- and azacytidine-treated cells
are shown in Figure 2(a-c), respectively. The hydrogen
peroxide- and azacytidine-treated myeloma cells dis-
played characteristic features of necrosis, including cell
swelling, translucent cytoplasm, cell membrane disrup-
tion, pyknotic nuclei, and excessive cellular debris. The
DNA content of necrotic cells was analyzed by gel
Figure 2 Morphologic images of myeloma cells. (a) untreated cells; (b) 100 μM azacytidine-treated cells for 24 h; and (c) H2O2-treated U266
cells; All images were captured by Olympus IX2-UCB 60× inverted microscopy; (d-e) detection of ROS in untreated and azacytidine-treated U266
cells using the Image-iT LIVE Reactive Oxygen Species (ROS) Kit. Cells were labeled with carboxy-H2DCFDA, which exhibited green fluorescence
when reacted with ROS, and nuclei were stained with blue-fluorescent Hoechst 33342. (d) untreated U266 cells; and (e) azacytidine-treated cells;
and (f) gel electrophoresis of DNA from untreated and azacytidine-treated myeloma cells.
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and azacytidine-treated cells (Figure 2(f )) shows that
DNA from azacytidine-treated cells exhibited a random
and general cleavage pattern and produced a smear that
further confirmed that azacytidine-induced cell death
occurs mainly via necrosis. The above data suggests that
oxidative stress may cause necrosis in azacytidine- or
hydrogen peroxide–treated cells. To confirm that ROS
contributes to azacytidine induced cell necrosis, an
Image-iT LIVE Reactive Oxygen Species (ROS) Kit was
used to detect ROS in the untreated and azacytidine-
treated cells. Cells were labeled with carboxy-H2DCFDA,
which fluoresces when oxidized by ROS, and nuclei were
stained with blue-fluorescent Hoechst 33342. Theazacytidine-treated cells exhibited much stronger green
fluorescence (Figure 2(e)) in comparison to untreated
cells (Figure 2(d)), indicating that azacytidine induced a
significant increase in ROS.
Proteomic analysis and identification of cell-bound
albumin in myeloma cell necrosis
Next, proteomic analysis was carried out on the necrotic
myeloma cells. An equal amount of proteins (30 μg)
from untreated- and azacytidine-treated U266 cells were
separated by 1D SDS-PAGE (Figure 3). Differentially
expressed proteins were immediately visible in the gel
band circled with a square. The intensity of the band at
about 70 kDa showed the largest change between
Figure 3 The 1D SDS-PAGE gel image of untreated and 24 h,
azacytidine-treated myeloma cells. Lane 1, molecular weight
markers; Lane 2, proteins from untreated cells; Lane 3, proteins from
5 μM azacytidine-treated cells; Lane 4, proteins from 10 μM
azacytidine-treated cells; Lane 5, proteins from 20 μM azacytidine-
treated cells; Lane 6, proteins from 40 μM azacytidine-treated cells;
and Lane 7, proteins from 80 μM azacytidine-treated cells;. The band
with the most differentially expressed proteins was marked with
a square.
Figure 4 Functional classification of differentially regulated proteins w
proteins related with each category are shown in brackets.
Tian et al. Proteome Science 2013, 11:24 Page 6 of 11
http://www.proteomesci.com/content/11/1/24untreated- and azacytidine-treated samples and become
more intense with higher concentrations of azacytidine.
The gel band was analyzed and the major protein was
identified in this band as human albumin, production of
which is a hallmark of hepatocytes. Previous studies have
shown that monocytes were capable of differentiation
into hepatocytes under different conditions, and also
that microglial cells in brain synthesized albumin
[38-41]. In order to determine whether the cell-bound
albumin originated from azacytidine-treated myeloma
cells, a human albumin-specific antibody was used for
western blot analysis. However, the antibody not only
recognized the proteins in the 70 kDa band, but it also
recognized bovine serum albumin (data not shown), pro-
moting us to verify the MS/MS spectra of tryptic pep-
tides matched those of human albumin. In fact, MS/MS
spectra matched to human albumin by searching a human
protein database also matched to sequences of tryptic pep-
tides of bovine serum albumin (BSA). Furthermore, many
unidentified MS/MS spectra also matched to peptide se-
quences of BSA. One of spectra is shown in Additional file
2: Figure S1. Indeed, searching a bovine protein database
led to identification of BSA with sequence coverage of
86% of BSA sequence, demonstrating that BSA was
enriched in necrotic cells. Furthermore, the intense band
was no longer visible by 1D SDS-PAGE when myelomaith PANTHER (http://www.pantherdb.org). The numbers of
Table 1 Up-regulated proteins after treatment with
100 μM azacytidine
Up regulated proteins Fold changes
IPI00784154 60 kDa heat shock protein, mitochondrial 2.4
IPI00010796 Protein disulfide-isomerase 2.0





protein glycosyltransferase subunit 1 2.1
IPI00453473 Histone H4 2.0
IPI00556485 RPLP0 protein 1.6
IPI00216691 Profilin-1 2.5
IPI00018206 Aspartate aminotransferase, mitochondrial 2.8
IPI00440493 ATP synthase subunit alpha, mitochondrial 2.8
IPI00020416 Tripeptidyl-peptidase 2 1.6
IPI00291006 Malate dehydrogenase, mitochondrial 3.3
IPI00339274 Histone H2A type 2-C 2.7
IPI00642982 LONP1 protein 2.3
IPI00018534 Histone H2B type 1-L 2.5
IPI00294398 Isoform 1 of Hydroxyacyl-coenzyme A
dehydrogenase, mitochondrial 1.8
IPI00006482 Isoform Long of Sodium/potassium-
transporting ATPase subunit alpha-1 2.1
IPI00030363 Acetyl-CoA acetyltransferase,
mitochondrial 1.8
IPI00303476 ATP synthase subunit beta, mitochondrial 3.4
IPI00216308 Voltage-dependent anion-selective
channel protein 1 3.3
IPI00017334 Prohibitin 2.5
IPI00001539 3-ketoacyl-CoA thiolase, mitochondrial 2.0
IPI00008529 60S acidic ribosomal protein P2 1.8
IPI00013808 Alpha-actinin-4 1.9
IPI00413611 DNA topoisomerase 1 1.8
IPI00759715 Isoform Cytoplasmic of
Fumaratehydratase, mitochondrial 1.6
IPI00646304 Peptidyl-prolylcis-trans isomerase B 1.7
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with 100 μM azacytidine, confirming that BSA originated
from cell culture medium.
Using western blot analysis, we confirmed that enrich-
ment of cell-bound albumin was a concentration-
dependent event Additional file 3: Figure S2 (a)). The
intensity of the BSA band became more intense when
cells were treated with higher concentrations of
azacytidine for 24 h. Moreover, western blotting also
shows the up-regulation of HSP60 when cells were
treated with higher concentrations of azacytidine. A re-
cent study has shown that HSP60 localizes in the tumor
cell plasma membrane associated with lipid rafts [42]. In
order to determine whether BSA binds to HSP60 in nec-
rotic myeloma cells, we used an anti-BSA antibody to
immune-precipitate BSA and associated proteins from
untreated and azacytidine-treated myeloma cells. Immu-
noprecipitated proteins were separated and probed with
anti-HSP60 antibodies, and western blot analysis showed
that HSP60 was co-immunoprecipitated by an anti-BSA
antibody (Additional file 3: Figure S2 (b)). An early study
shows that the cell-bound albumin binds to peptidogly-
can-, lipopolysacchride-, and lipoteichoic acid in lym-
phocytes and macrophages [43]. Our data indicate that
HSP60 is an additional binding partner of the cell-bound
albumin.
A similar protein band pattern by 1D SDS-PAGE was
exhibited in Additional file: 4: Figure S3 for U266 cells
treated with hydrogen peroxide, showing the characte-
ristic band of enriched cell-bound albumin at about
70 kDa. Moreover, enrichment of BSA was observed in
other myeloma cell lines RPMI8226 and NCI-H929
when they were treated with azacytidine (Additional file
5: Figure S4). It is worth mentioning that enrichment of
albumin is not observed in azacytidine-treated non-
hematopoietic cell lines including A549, A2780, and
HUH-7 from lung, ovarian, and liver cancer, respectively.
Taken together, out data suggest that enrichment of cell-
bound albumin was unique to oxidative stress induced-
necrosis in myeloma cell lines.
Oxidative stress-induced over-expression of ER- and
mitochondrial-specific chaperones in necrotic myeloma
cells
We also identified changes of expression levels in other
proteins in azacytidine-treated cells. Using label-free
quantitation method by spectra counts and the extracted
ion current, we showed that expression levels of 79 pro-
teins were changed upon azacytidine treatment. These
proteins participate in diverse cellular activities including
transporting, nucleic acid binding, hydrolase activities,
calcium-binding, membrane trafficking, chaperoning,
and receptor binding (Figure 4), in which 17 proteins
interact with nucleic acid and 11 proteins are molecularchaperones. Twenty nine up-regulated and 50 down-
regulated proteins are listed in Table 1 and Table 2, re-
spectively. Nineteen up-regulated proteins are known
ER- and mitochondrialspecific proteins. ER is a multi-
functional organelle that plays an essential role in pro-
tein folding, assembly and quality control of secretory
and membrane proteins, disulfide bond formation, gly-
cosylation, lipid biosynthesis, Ca2+ storage and signaling.
Significant changes of ER- and mitochondrial proteins
indicate that they are main targets of azacytidine-
induced oxidative stress.





IPI00003865 Isoform 1 of Heat shock cognate
71 kDa protein 0.5
IPI00414676 Heat shock protein HSP 90-beta 0.7
IPI00784295 Isoform 1 of Heat shock protein HSP 90-alpha 0.6
IPI00220740 Isoform 2 of Nucleophosmin 0.2
IPI00018465 T-complex protein 1 subunit eta 0.7
IPI00179330 Ubiquitin-40S ribosomal protein S27a 0.4
IPI00985384 ATP-dependent RNA helicase DDX3X isoform 3 0.2
IPI00027547 Dermcidin 0.2
IPI00376143 DNA replication licensing factor
MCM7 isoform 2 0.3
IPI00786995 DNA-dependent protein kinase
catalytic subunit-like 0.2
IPI00002966 Heat shock 70 kDa protein 4 0.4
IPI00027107 elongation factor Tu, mitochondrial precursor 0.4
IPI00026781 Fatty acid synthase 0.4
IPI00015018 Inorganic pyrophosphatase 0.5
IPI00008557 Insulin-like growth factor 2 mRNA-binding
protein 1 0.4
IPI00000816 Isoform 1 of 14-3-3 protein epsilon 0.5
IPI00658000 Isoform 1 of Insulin-like growth factor
2 mRNA-binding protein 3 0.1
IPI00455383 Isoform 2 of Clathrin heavy chain 1 0.5
IPI00883762 Isoform 2 of Cytosolic acyl coenzyme A
thioester hydrolase 0.1
IPI00025273 Isoform Long of Trifunctional purine
biosynthetic protein adenosine-3 0.4
IPI00216230 Lamina-associated polypeptide 2,
isoform alpha 0.5
IPI00170935 Leucine-rich repeat-containing protein 47 0.1
IPI00017297 Matrin-3 0.1
IPI00016610 Poly(rC)-binding protein 1 0.5
IPI00017617 Probable ATP-dependent RNA helicase DDX5 0.5
IPI00550451 Serine/threonine-protein phosphatase
PP1-alpha catalytic subunit 0.2
IPI00947285 suprabasin isoform 1 precursor 0.3
IPI00216049 Isoform 1 of Heterogeneous nuclear
ribonucleoprotein K 0.1
IPI01011912 Phosphoglycerate kinase 0.5
IPI00549725 Phosphoglyceratemutase 1 0.2
IPI00645452 Tubulin, beta 0.3
IPI00179964 Isoform 1 of Polypyrimidine
tract-binding protein 1 0.3
IPI00217465 Histone H1.2 0.4
IPI00783271 Leucine-rich PPR motif-containing
protein, mitochondrial 0.5
IPI00219365 Moesin 0.6
Table 2 Down-regulated proteins after treatment with
100 μM azacytidine (Continued)
IPI00396485 Elongation factor 1-alpha 1 0.4
IPI00419258 High mobility group protein B1 0.3
IPI00031812 Nuclease-sensitive element-binding protein 1 0.3
IPI00465439 Fructose-bisphosphatealdolase A 0.5
IPI00217223 Multifunctional protein ADE2 0.4
IPI00550363 Transgelin-2 0.5
IPI00917777 116 kDa U5 small nuclear ribonucleoprotein
component isoform b 0.5
IPI00100160 Isoform 1 of Cullin-associated
NEDD8-dissociated protein 1 0.5
IPI00793443 Isoform 1 of Importin-5 0.4
IPI00449049 Poly [ADP-ribose] polymerase 1 0.6
IPI00007797 Fatty acid-binding protein, epidermal 0.4
IPI00398625 Hornerin 0.4
IPI00843975 Ezrin 0.6
IPI00465248 Isoform alpha-enolase of Alpha-enolase 0.5
IPI00645078 Ubiquitin-like modifier-activating enzyme 1 0.4
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protein disulfide isomerase (PDI), endoplasmin, calreti-
culin, and calnexin were all upregulated in U266 cells
upon azacytidine treatment as indicated by changes of
spectra counts (Figure 5(a)), showing that expression
level of HSP60 has three-fold increase in necrotic cells.
Up-regulation of HSP60 was also confirmed by western
blotting (Additional file 3: Figure S2 (a)). Protein abun-
dance index (PAI) was calculated based on the number
of observed peptides per protein normalized by the the-
oretical number of peptides (Additional file 6: Table S2),
showing that the relative concentration of HSP60 is 2
times higher than those of other four chaperones. It has
been shown that HSP60 is essential in the synthesis and
transportation of essential mitochondrial proteins [44]
and that HSP60 is up-regulated to protect cellular sur-
vival under toxic or stressful circumstances [45-47]. Our
data demonstrates that expression level of HSP60 is
highly up-regulated under oxidative stress, suggesting
HSP60 may serve as a new target in myeloma treatment.
PDI catalyzes formation and breakage of disulfide
bonds for proteins to achieve their fully folded state and
aids wrongly folded proteins to reach a correctly folded
state as a chaperone [48,49]. Endoplasmin chaperone
functions in the processing and transport of secreted
proteins in ER and possesses the ATPase activity and
calcium-binding property. Calreticulin is a lectin-like,
calcium binding ER-specific chaperone that binds to
misfolded proteins and prevents them from being
exported from the ER to the Golgi apparatus. Overex-
pression of calreticulin in many cancer cells promotes
Figure 5 Azacytidine induced changes in chaperones. (a) The
fold of changes of ER- and mitochondrial chaperones from the
untreated and 100 μM azacytidine-treated U266 cells for 24 h; (b)
The fold of changes of cytosolic and nuclear chaperones from
untreated and 100 μM azacytidine-treated U266 cells for 24 h. The
number on the y axis represents spectra counts for each
identified protein.
Figure 6 qPCR analysis of HSP90 and HSP71 from untreated
cells and cells treated with 40 μM and 80 μM azacytidine
for 24 h.
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Azacytidine also induces up-regulation of calnexin
(CNX), whose main function is to assist protein folding
and quality control. Calreticulin, calnexin, and ERp57
constitute the calreticulin/calnexin cycle functioning in
the quality control of transmembrane and secreted gly-
coproteins in ER. Up-regulation of ER-specific chaper-
ones indicates that oxidative stress activates intracellular
signal transduction pathways and induces the transcrip-
tional upregulation of genes to enhance the ER protein-
folding capacity and quality control. Azacytidine induced
up-regulation of mitochondrial and ER-chaperones were
also observed in other treated myeloma cells as quanti-
fied by TMT labeling (Additional file 7: Table S3).
Necrosis-induced release of HSP71 and HSP90 into the
cell medium
Expression levels in 50 proteins were down-regulated
upon azacytidine treatment including 22 nucleus-
specific proteins and 21 nucleotide binding proteins.
Five chaperones were down-regulated including chaper-
onin containing TCP1 subunit 7 (eta), HSP71, HSP90
alpha (cytosolic), HSP90 beta, and nucleophosmin 2
(Figure 5(b)). To confirm azacytidine-induced down-regulation of HSP90 and HSP71, qPCR analysis was car-
ried out, and showed that the expression of HSP90 and
HSP71 at the mRNA level is down-regulated after
azacytidine treatment (Figure 6). HSP71 is the major
chaperone involving in protein folding and protects pro-
teins against aggregation in cytosol. Extensive studies
have shown that HSP71 is detected outside cells, where
it is thought to activate the immune system [51-53]. In
order to determine whether necrotic myeloma cells re-
lease HSP71 into cell medium, we analyzed proteins in
culture medium of untreated and azacytidine-treated
cells. Using TMT labeling, we found that relative con-
centrations of HSP71 and HSP90 were two times higher
in medium of necrotic cells than those of untreated cells
(Additional file 8: Figure S5), demonstrating enhanced
release of HSP71 and HSP90 from necrotic cells into the
cell culture medium. HSP71 does not have a consensus
sequence for secretion, and the mechanism for trans-
location of this protein across membranes may involve
in the binding of HSP71 with the plasma membrane be-
fore release into the extracellular environment. Chaper-
onin containing TCP-1 is a cytoplasmic protein and
plays an important role in folding of alpha and beta
tubulin. The expression level of nucleophosmin has the
largest decrease upon azacytidine-treatment Figure 5(b).
Nucleophosmin 2 is a histone chaperone located in the
nucleolus, but it can be translocated to the nucleoplasm
in response to serum starvation or drug treatment.
Other down-regulated proteins participated in diverse
activities such as nucleotide-binding, metabolic pro-
cesses, and RNA binding (Table 2). Azacytidine is an
inhibitor for DNA methyltransferase. We did not deter-
mine azacytidine-induced changes in DNA methylation
in current study. We hypothesize that changes in gene
expressions are attributable to both azacytidine induced
epigenetic changes and ROS signaling. Great efforts are
Tian et al. Proteome Science 2013, 11:24 Page 10 of 11
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azacytidine induced necrosis in myeloma cells.Conclusions
Taken together, our results show that azacytidine and
hydrogen peroxide induce necrosis in myeloma cells
through oxidative stress, resulting in enrichment of
cell-bound albumin and up-regulation of ER- and
mitochondrial-specific chaperones and suggesting that
mitochondria and ER are major targets of ROS. Expres-
sion levels of HSP90 and HSP71 are down-regulated in
azacytidine-treated cells, concomitant with enhanced re-
lease of these cytosolic chaperones into the cell culture
medium. Inhibition of HSP60 may be a new therapeutic
approach for myeloma treatment.Additional files
Additional file 1: Table S1. Primers used for qPCR analysis in this work.
Additional file 2: Figure S1. The MS/MS spectrum of a doubly charged
peptide ion at m/z 863 for MH2
2+ corresponding to the mass of the
peptide MPCTEDYLSLILNR) from Bovine serum albumin,with four amino
acids difference from human serum albumin.
Additional file 3: Figure S2. Western blot analysis of BSA and HSP60 in
azacytidine treated cells. (a) Western blot analysis of HSP60 and BSA from
untreated and U266 cells treated with 20 μM, 40 μM, and 80 μM
azacytidine for 24 h. Lane 1, before treatment; Lane 2, 20 μM; Lane 3,
40 μM; and Lane 4, and 80 μM. (b) Western blot analysis of HSP60 after
anti-BSA antibody-immunoprecipitation.
Additional file 4: Figure S3. The 1D SDS-PAGE gel image of proteins
from untreated and H2O2-treated U266 cells. Lane 1, molecular weight
markers; Lane 2, proteins from untreated cells; Lane 3, proteins from
2.5 mM H2O2-treated U266 cells; Lane 4, proteins from 5 mM H2O2-
treated cells. The band with differentially expressed proteins was marked
with a square.
Additional file 5: Figure S4. The 1D SDS-PAGE gel image of proteins
from untreated and azacytidine-treated RPMI8226 and NCI-H929 cells.
Lane 1, molecular weight markers; Lane 2, proteins from untreated cells;
Lane 3, proteins from 80 μM azacytidine-treated RPMI8226 cells; Lane 4,
molecular weight markers; Lane 5, proteins from untreated NCI-H929
cells; Lane 6, proteins from 80 μM azacytidine-treated NCI-H929 cells. The
band with differentially expressed proteins was marked with a square.
Additional file 6: Table S2. Estimated protein abundance index (PAI) of
HSP60, PDI, endoplasmin, calreticulin, and calnexin in untreated and 24 h,
100 μM azacytidine-treated U266 cells.
Additional file 7: Table S3. Relative concentration ratios of selected
proteins in untreated and azacytidine-treated RPMI8226 and NCI-H929
cells as determined by TMT-labeling, respectively.
Additional file 8: Figure S5. MS/MS spectra of TMT-labeled peptides
of HSP71 and HSP90. (a) The MS/MS spectrum of a doubly charged ion
at m/z 739.89 for MH2
2+ corresponding to the mass of the peptide
TMT-labeled FEELNADLFR. The labeled peaks correspond to masses of y
and b ions of the modified peptide; (b) The MS/MS spectrum of a triply
charged ion at m/z 465.25 for MH3
3+ corresponding to the mass of the
TMT-labeled peptide LGIHEDSQNR. The labeled peaks correspond to
masses of y and b ions of the modified peptide. Figure inserts show
peaks of TMT reporter ions of two labeled peptides.Competing interests
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